Saleh MD, Mansoor

Year	Title	Altmetric
2019	Bridging the Gap in Training and Clinical Practice in Sub-Saharan Africa 2019
2019	Promoting Breast Cancer Awareness and Clinical Breast Examination in the LMIC: Experiences from Tajikistan, Pakistan and Kenya 2019
2019	Phase 1b trial of nintedanib in combination with bevacizumab in patients with advanced solid tumors 2019
2019	Breast Cancer knowledge, perceptions and practices in a rural Community in Coastal Kenya 2019
2019	Changes in health-related quality of life with long-term eltrombopag treatment in adults with persistent/chronic immune thrombocytopenia: Findings from the EXTEND study 2019
2018	Targetable vulnerabilities in T- and NK-cell lymphomas identified through preclinical models 2018
2018	So You want to be a principal investigator 2018
2018	Promoting clinical breast evaluations in a lower middle-income country setting: An approach toward achieving a sustainable breast health program 2018
2018	Ethnicity and breast cancer characteristics in Kenya 2018
2017	Safety and efficacy of long-term treatment of chronic/persistent ITP with eltrombopag: Final results of the EXTEND study 2017
2017	Safety and antitumor activity of apalutamide (ARN-509) in metastatic castration-resistant prostate cancer with and without prior abiraterone acetate and prednisone 2017
2017	Academic cancer center phase i program development 2017
2017	Androgen receptor mutations in patients with castration-resistant prostate cancer treated with apalutamide 2017
2016	Comparison of two dosing schedules for subcutaneous injections of low-dose anti-CD20 veltuzumab in relapsed immune thrombocytopenia 2016
2016	Breast camps for awareness and early diagnosis of breast cancer in countries with limited resources: A multidisciplinary model from Kenya 2016
2016	Phase II study of a novel taxane (Cabazitaxel-XRP 6258) in previously treated advanced non-small cell lung cancer (NSCLC) patients 2016
2016	Long-term outcomes after adjuvant treatment of sequential versus combination docetaxel with doxorubicin and cyclophosphamide in node-positive breast cancer: BCIRG-005 randomized trial 2016
2016	A community-oriented approach to breast cancer in a low-resource setting: Improving awareness, early detection and treatment of breast cancer in Tajikistan 2016
2015	Phase I/IIa study of sequential chemotherapy regimen of bendamustine/irinotecan followed by etoposide/carboplatin in untreated patients with extensive disease small cell lung cancer (EDSCLC) 2015
2015	EMERGE: A randomized phase II study of the antibody-drug conjugate glembatumumab vedotin in advanced glycoprotein NMB - Expressing breast cancer 2015
2015	SPIRITT: A randomized, multicenter, phase II study of panitumumab with FOLFIRI and bevacizumab with FOLFIRI as second-line treatment in patients with unresectable wild type KRAS metastatic colorectal cancer 2015
2014	Phase III study of iniparib plus gemcitabine and carboplatin versus gemcitabine and carboplatin in patients with metastatic triple-negative breast cancer 2014
2014	Phase I/II study of the antibody-drug conjugate glembatumumab vedotin in patients with locally advanced or metastatic breast cancer 2014
2014	A phase I trial of LY2510924, a CXCR4 peptide antagonist, in patients with advanced cancer 2014
2014	A phase I dose escalation study of oral c-MET inhibitor tivantinib (ARQ 197) in combination with gemcitabine in patients with solid tumors 2014
2014	A randomized, phase II study of the anti-insulin-like growth factor receptor type 1 (IGF-1R) monoclonal antibody robatumumab (SCH 717454) in patients with advanced colorectal cancer 2014
2014	Assessment of treatment and monitoring patterns and subsequent outcomes among patients with chronic myeloid leukemia treated with imatinib in a community setting 2014
2014	Is breast cancer from Sub Saharan Africa truly receptor poor? Prevalence of ER/PR/HER2 in breast cancer from Kenya 2014
2014	Severe neutropenia and relative dose intensity among patients <65 and ≥65 years with non-Hodgkin's lymphoma receiving CHOP-based chemotherapy 2014
2013	Treatment rationale and study design for a randomized, double-blind, placebo-controlled phase II study evaluating onartuzumab (MetMAb) in combination with bevacizumab plus mFOLFOX-6 in patients with previously untreated metastatic colorectal cancer 2013
2013	Breast cancer diagnosis in a resource poor environment through a collaborative multidisciplinary approach: The Kenyan experience 2013
2013	Repeated short-term use of eltrombopag in patients with chronic immune thrombocytopenia (ITP) 2013
2013	Safety and efficacy of eltrombopag for treatment of chronic immune thrombocytopenia: Results of the long-term, open-label EXTEND study 2013
2013	Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine 2013
2013	Low-dose anti-CD20 veltuzumab given intravenously or subcutaneously is active in relapsed immune thrombocytopenia: A phase I study 2013
2013	Phase 2, multicenter, open-label study of tigatuzumab (CS-1008), a humanized monoclonal antibody targeting death receptor 5, in combination with gemcitabine in chemotherapy-naive patients with unresectable or metastatic pancreatic cancer 2013
2013	Safety and efficacy of eltrombopag for treatment of chronic immune thrombocytopenia: Results of the long-term, open-label EXTEND study 2013
2012	Therapeutic optimization of aromatase inhibitor-associated arthralgia: Etiology, onset, resolution, and symptom management in early breast cancer 2012
2012	Phase I study of bosutinib, a Src/Abl tyrosine kinase inhibitor, administered to patients with advanced solid tumors 2012
2011	Phase III study of doxorubicin/cyclophosphamide with concomitant versus sequential docetaxel as adjuvant treatment in patients with human epidermal growth factor receptor 2-normal, node-positive breast cancer: BCIRG-005 trial 2011
2011	Eltrombopag for chronic immune thrombocytopenia - Authors' reply 2011
2011	Abiraterone and increased survival in metastatic prostate cancer 2011
2011	Eltrombopag for management of chronic immune thrombocytopenia (RAISE): A 6-month, randomised, phase 3 study (Lancet (2011) 377, (393-402)) 2011
2011	Eltrombopag for management of chronic immune thrombocytopenia (RAISE): A 6-month, randomised, phase 3 study 2011
2011	Sunitinib plus paclitaxel versus bevacizumab plus paclitaxel for first-line treatment of patients with advanced breast cancer: A phase III, randomized, open-label trial 2011
2010	Phase II trial of weekly nanoparticle albumin-bound paclitaxel with carboplatin and trastuzumab as first-line therapy for women with HER2-overexpressing metastatic breast cancer 2010
2010	Pilot trial of preoperative (Neoadjuvant) letrozole in combination with bevacizumab in postmenopausal women with newly diagnosed estrogen receptor-or progesterone receptor-positive breast cancer 2010
2010	A multicenter phase II trial of carboplatin and cetuximab for treatment of advanced nonsmall cell lung cancer 2010
2010	Phase I trial of weekly tigatuzumab, an agonistic humanized monoclonal antibody targeting death receptor 5 (DR5) 2010
2010	Pemetrexed with or without matuzumab as second-line treatment for patients with stage IIIB/IV non-small cell lung cancer 2010
2009	Analysis of the impact and burden of illness of adult chronic ITP in the US 2009
2009	Multicenter randomized phase II study of weekly or twice-weekly bortezomib plus rituximab in patients with relapsed or refractory follicular or marginal-zone B-cell lymphoma 2009
2009	High-dose imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: High rates of rapid cytogenetic and molecular responses 2009
2009	A randomized, phase II trial of two dose schedules of carboplatin/ paclitaxel/cetuximab in stage IIIB/IV non-small-cell lung cancer (NSCLC) 2009
2009	Data-driven medical decision-making in managing chemotherapy-induced nausea and vomiting 2009
2009	Impact of NCD guidelines on Medicare patients with chemotherapy-induced anemia receiving erythropoiesis-stimulating agents: Results from a community oncology practice 2009
2007	Phase II study of KOS-862 in patients with metastatic androgen independent prostate cancer previously treated with docetaxel 2007
2007	Eltrombopag for the treatment of chronic idiopathic thrombocytopenic purpura 2007
2007	Double-blinded randomized study of high-dose calcitriol plus docetaxel compared with placebo plus docetaxel in androgen-independent prostate cancer: A report from the ASCENT investigators 2007
2007	Bendamustine in non-Hodgkin lymphoma: The double-agent that came from the cold war 2007
2006	Phase II multicenter study of arsenic trioxide in patients with myelodysplastic syndromes 2006
2005	Effect of docetaxel chemotherapy on the activity of a gonadotropin releasing hormone vaccine in patients with advanced prostate cancer 2005
2005	Phase I/IIa study of cetuximab with gemcitabine plus carboplatin in patients with chemotherapy-naïve advanced non-small-cell lung cancer 2005
2004	Safety of treatment of metastatic breast cancer with trastuzumab beyond disease progression 2004
2004	Phase 2 study of arsenic trioxide in patients with relapsed or refractory multiple myeloma 2004
2003	Monoclonal antibody therapy of non-Hodgkin's lymphoma: the Rituximab story. 2003
2002	A phase I trial of the single-chain immunotoxin SGN-10 (BR96 sFv-PE40) in patients with advanced solid tumors 2002
2002	Treatment with ibritumomab tiuxetan radioimmunotherapy in patients with rituximab-refractory follicular non-Hodgkin's lymphoma 2002
2002	Ibritumomab tiuxetan radioimmunotherapy for patients with relapsed or refractory non-Hodgkin lymphoma and mild thrombocytopenia: A phase II multicenter trial 2002
2002	Yttrium 90 ibritumomab tiuxetan radioimmunotherapy for relapsed or refractory low-grade non-hodgkin's lymphoma 2002
2001	A pilot trial of Vitaxin, a humanized anti-vitronectin receptor (anti αvβ3) antibody in patients with metastatic cancer 2001
2001	Pivotal study of iodine I 131 tositumomab for chemotherapy-refractory low-grade or transformed low-grade B-cell non-Hodgkin's lymphomas 2001
2001	Phase I study of anti-epidermal growth factor receptor antibody cetuximab in combination with radiation therapy in patients with advanced head and neck cancer 2001
2001	Clearing of cells bearing the bcl-2 [t(14;18)] translocation from blood and marrow of patients treated with rituximab alone or in combination with CHOP chemotherapy 2001
2000	A pilot study of anti-cd20 moab mtuximab in patients with refractory immune thrombocytopenic purpura (TTP) 2000
2000	BR96-doxorubicin: Been there, done that! [1] (multiple letters) 2000
2000	Oral chlorambucil and prednisone with rituximab as initial chemotherapy for low grade non hodgkin's lymphoma: a phase ii trial 2000
2000	Multicenter phase II study of iodine-131 tositumomab for chemotherapy- relapsed/refractory low-grade and transformed low-grade B-cell non-Hodgkin's lymphomas 2000
2000	Phase I trial of the anti-Lewis Y drug immunoconjugate BR96-doxorubicin in patients with Lewis Y-expressing epithelial tumors 2000
1999	Phase I trial of a recombinant vaccinia virus encoding carcinoembryonic antigen in metastatic adenocarcinoma: Comparison of intradermal versus subcutaneous administration 1999
1999	NCCN practice guidelines for Hodgkin's disease 1999
1999	Randomized phase II study of BR96-doxorubicin conjugate in patients with metastatic breast cancer 1999
1999	Combined modality therapy of A431 human epidermoid cancer using anti- EGFR antibody C225 and radiation 1999
1999	Treatment of patients with low-grade B-cell lymphoma with the combination of chimeric anti-CD20 monoclonal antibody and CHOP chemotherapy 1999
1998	Diphtheria toxin fusion proteins 1998
1998	Phase I trial of a ligand fusion-protein (DAB389IL-2) in lymphomas expressing the receptor for interkeukin-2 1998
1998	Antitumor activity of DAB389IL-2 fusion toxin in mycosis fungoides 1998
1998	Chimeric antibodies with specificity for tumor antigens: Demonstration of in situ localization to tumors after antibody therapy 1998
1998	Immunologic response to the dual murine anti-id vaccine melimmune-1 and melimmune-2 in patients with high-risk melanoma without evidence of systemic disease 1998
1997	A novel gene therapy strategy for elimination of prostate carcinoma cells from human bone marrow 1997
1997	Correlation of toxicity with treatment parameters for ¹³¹I-CC49 radioimmunotherapy in three phase II clinical trials 1997
1996	Phase Ia/Ib trial of Anti-GD2 chimeric monoclonal antibody 14.18 (ch l4.18) and recombinant human granulocyte-macrophage colony-stimulating factor (rhGM-CSF) in metastatic melanoma 1996
1995	Phase II Trial of Murine Monoclonal Antibody D612 Combined with Recombinant Human Monocyte Colony-stimulating Factor (rhM-CSF) in Patients with Metastatic Gastrointestinal Cancer 1995
1995	CD16⁺ monocytes in patients with cancer: Spontaneous elevation and pharmacologic induction by recombinant human macrophage colony-stimulating factor 1995
1995	Phase I trial of an anti-cd19 deglycosylated ricin a chain immunotoxin in non-hodgkin's lymphoma: Effect of an intensive schedule of administration 1995
1993	A Phase I Clinical Trial of Murine Monoclonal Antibody D612 in Patients with Metastatic Gastrointestinal Cancer 1993
1993	Generation of a human anti-idiotypic antibody that mimics the GD2 antigen 1993
1992	Frequent anti-V-region immune response to mouse B72.3 monoclonal antibody 1992
1992	Advances in monoclonal antibody therapy of cancer 1992
1992	Monoclonal antibody therapy of cancer 1992
1992	Phase I Trial of the Murine Monoclonal Anti-GD2 Antibody 14G2a in Metastatic Melanoma 1992
1992	Phase I trial of iodine-131-chimeric B72.3 (human IgG4) in metastatic colorectal cancer 1992
1992	Phase I trial of the chimeric anti-GD2 monoclonal antibody ch14.18 in patients with malignant melanoma 1992
1992	Selection of platelets for refractory patients by HLA matching and prospective crossmatching 1992
1991	Pharmacokinetics and Immune Response of 131I-ChimericMouse/Human B72.3 (Human 74) Monoclonal Antibody in Humans 1991
1991	Evidence for the Elevation of Serum Carcinoembryonic Antigen and Tumor-associated Glycoprotein-72 Levels in Patients Administered Interferons 1991
1991	In-111 labeled monoclonal anti-carcinoembryonic antigen antibody (ZCE025) in the immunoscintigraphic imaging of metastatic antigen-producing adenocarcinomas 1991
1991	Pharmacokinetics, immune response, and biodistribution of iodine-131-labeled chimeric mouse/human IgG1,k 17-1A monoclonal antibody 1991
1990	A phase II trial of murine monoclonal antibody 17-1A and interferon-γ: Clinical and immunological data 1990
1990	Initial evaluation of a human immunoglobulin M monoclonal antibody (HA-1A) in humans 1990
1990	Intravenous immunoglobulin therapy in systemic lupus erythematosus‐associated thrombocytopenia 1990
1989	Effect of intravenous gammaglobulin on circulating and platelet-bound antibody in immune thrombocytopenia 1989
1989	Intrathecal cytosine arabinoside-induced acute, rapidly reversible paralysis 1989
1989	Monocyte-platelet interaction in immune and nonimmune thrombocytopenia 1989
1989	Quinidine-induced immune thrombocytopenia 1989
1988	Phase I trial of multiple large doses of murine monoclonal antibody CO17-1A. I. Clinical aspects 1988
1988	Phase I trial of multiple large doses of murine monoclonal antibody Co17-1A. II. Pharmacokinetics and immune response 1988
1988	Clinical use of a standard kit-preparation of radiolabeled monoclonal antibody 96.5 in the diagnostic imaging of metastatic melanoma 1988
1988	Effect of commercial immunoglobulin G preparation on human monocyte Fc-receptor dependent binding of antibody coated platelets 1988
1987	Platelet surface-bound IgG in patients with immune and nonimmune thrombocytopenia 1987
1987	Immune thrombocytopenia: Effects of maternal gamma globulin infusion on maternal and fetal serum, platelet, and monocyte IgG: Case Report 1987
1986	Phase I clinical trial of CO17-1A monoclonal antibody 1986
1986	In vitro effects of gammaglobulin (IgG) on human monocyte Fc receptor function. I. Effect on monocyte membrane‐associated IgG and Fc receptor‐dependent binding of antibody‐coated platelets 1986

Year

Title

Altmetric

2019

Bridging the Gap in Training and Clinical Practice in Sub-Saharan Africa 2019

2019

Promoting Breast Cancer Awareness and Clinical Breast Examination in the LMIC: Experiences from Tajikistan, Pakistan and Kenya 2019

2019

Phase 1b trial of nintedanib in combination with bevacizumab in patients with advanced solid tumors 2019

2019

Breast Cancer knowledge, perceptions and practices in a rural Community in Coastal Kenya 2019

2019